Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.


TSXV:QPT - Post by User

Quest Pharmatech Inc > Why did the Study fail?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by ARIMA11on Jan 24, 2024 8:07pm
97 Views
Post# 35844150

RE:RE:RE:RE:RE:Why did the Study fail?

RE:RE:RE:RE:RE:Why did the Study fail?
Again, 61% of the trades today involved Anonymous brokers (1)
 
24-Jan 0.02 95000 1 7
24-Jan 3:29:09 PM 0.02 10,000 1 7
24-Jan 3:28:54 PM 0.02 10,000 1 7
24-Jan 12:55:23 PM 0.025 29,000 2 1
24-Jan 10:19:47 AM 0.025 29,000 1 19
24-Jan 10:19:39 AM 0.025 5,000 1 19
24-Jan 10:19:19 AM 0.025 20,000 1 9
198,000
 
24-Jan 3:28:54 PM 0.02 10,000 79 7
24-Jan 3:28:54 PM 0.025 1,000 2 7
24-Jan 10:19:39 AM 0.025 30,000 7 19
24-Jan 9:30:00 AM 0.03 30,000 7 19
24-Jan 9:30:00 AM 0.03 1,000 80 19
24-Jan 9:30:00 AM 0.03 50,000 9 19
122,000
 
320,000
0.61875
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities